July 21, 2015 NR. Pharma has already taken a slice.

Hepalink and Eastern put up $50 million.

Despite missing the primary outcome in ASSURE, RVX analysis reveals a 77% RRR in MACE in diabetic patients from ASSURE and SUSTAIN.

Who cares about plaque reduction in a short study when you can show MACE reduction? That’s like looking for coal and finding high grade gold.

This finding allows RVX to get Phase 3 status for BetOnMACE despite protests from many stats gurus :)

bfw